Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
$4.24
-14.7%
$2.60
$2.03
$7.13
$279.25M0.47458,749 shs903,696 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$31.57
-0.8%
$38.32
$25.34
$60.08
$1.28B0.47316,030 shs107,971 shs
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$16.31
-6.2%
$13.78
$10.94
$23.75
$1.22B1.641.41 million shs1.75 million shs
Savara Inc. stock logo
SVRA
Savara
$6.16
+2.1%
$5.26
$1.98
$7.01
$1.27B0.261.60 million shs786,435 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
0.00%+77.50%+97.22%+78.14%+113.30%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
+0.38%+2.38%+3.31%-42.49%+23.97%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
+3.14%+14.18%+14.41%+53.08%-15.62%
Savara Inc. stock logo
SVRA
Savara
+2.20%+5.98%+15.96%+10.44%+172.85%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
$4.24
-14.7%
$2.60
$2.03
$7.13
$279.25M0.47458,749 shs903,696 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$31.57
-0.8%
$38.32
$25.34
$60.08
$1.28B0.47316,030 shs107,971 shs
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$16.31
-6.2%
$13.78
$10.94
$23.75
$1.22B1.641.41 million shs1.75 million shs
Savara Inc. stock logo
SVRA
Savara
$6.16
+2.1%
$5.26
$1.98
$7.01
$1.27B0.261.60 million shs786,435 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
0.00%+77.50%+97.22%+78.14%+113.30%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
+0.38%+2.38%+3.31%-42.49%+23.97%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
+3.14%+14.18%+14.41%+53.08%-15.62%
Savara Inc. stock logo
SVRA
Savara
+2.20%+5.98%+15.96%+10.44%+172.85%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
2.00
Hold$11.00144.44% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.00
Hold$42.5034.81% Upside
Schrodinger, Inc. stock logo
SDGR
Schrodinger
2.33
Hold$20.2516.04% Upside
Savara Inc. stock logo
SVRA
Savara
2.88
Moderate Buy$10.1468.35% Upside

Current Analyst Ratings Breakdown

Latest GALT, PAHC, SDGR, and SVRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2026
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
Reiterated RatingBuy$11.00
6/18/2026
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
UpgradeSell (E+)Sell (D-)
6/15/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
DowngradeBuy (B-)Hold (C+)
5/21/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
DowngradeStrong-BuyHold
5/14/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Lower Price TargetNeutral$62.00 ➝ $44.00
5/14/2026
Schrodinger, Inc. stock logo
SDGR
Schrodinger
Lower Price TargetEqual Weight$19.00 ➝ $17.00
5/8/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
DowngradeBuy (B)Buy (B-)
5/4/2026
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
DowngradeSell (D-)Sell (E+)
4/24/2026
Savara Inc. stock logo
SVRA
Savara
Initiated CoverageOutperform$9.00 ➝ $11.00
4/21/2026
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
Reiterated RatingSell (D-)
4/21/2026
Savara Inc. stock logo
SVRA
Savara
Reiterated RatingSell (D-)
(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/A($1.99) per shareN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.30B0.99$3.25 per share9.69$7.05 per share4.47
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$255.87M5.03N/AN/A$4.94 per share3.53
Savara Inc. stock logo
SVRA
Savara
N/AN/AN/AN/A$1.00 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$30.84M-$0.41N/AN/AN/AN/AN/A-164.69%8/13/2026 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$48.26M$2.3313.539.470.486.35%37.14%8.57%6/30/2026 (Confirmed)
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$103.26M-$1.41N/AN/AN/A-40.61%-30.85%-15.32%8/5/2026 (Estimated)
Savara Inc. stock logo
SVRA
Savara
-$118.84M-$0.56N/AN/AN/AN/A-87.19%-66.42%8/12/2026 (Estimated)

Latest GALT, PAHC, SDGR, and SVRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2026Q1 2026
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$0.06-$0.08-$0.02-$0.08N/AN/A
5/12/2026Q1 2026
Savara Inc. stock logo
SVRA
Savara
-$0.14-$0.15-$0.01-$0.15$0.50 millionN/A
5/6/2026Q3 2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.72$0.76+$0.04$0.59$367.02 million$383.54 million
5/5/2026Q1 2026
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$0.56-$0.81-$0.25-$0.81$47.57 million$58.59 million
3/31/2026Q4 2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$0.10-$0.08+$0.02-$0.08$36.32 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.52%N/A20.60%N/A
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/AN/AN/AN/AN/A
Savara Inc. stock logo
SVRA
Savara
N/AN/AN/AN/AN/A

Latest GALT, PAHC, SDGR, and SVRA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/5/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.121.51%6/3/20266/3/20266/24/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/A
2.15
2.15
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.97
3.17
1.26
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/A
2.74
2.74
Savara Inc. stock logo
SVRA
Savara
0.17
13.47
13.47

Institutional Ownership

CompanyInstitutional Ownership
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
11.68%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
79.05%
Savara Inc. stock logo
SVRA
Savara
87.93%

Insider Ownership

CompanyInsider Ownership
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
52.60%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
50.13%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
10.10%
Savara Inc. stock logo
SVRA
Savara
5.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
965.86 million31.22 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2,47540.56 million20.23 millionOptionable
Schrodinger, Inc. stock logo
SDGR
Schrodinger
79073.82 million66.37 millionOptionable
Savara Inc. stock logo
SVRA
Savara
20204.93 million194.07 millionOptionable

Recent News About These Companies

Savara Announces New Employment Inducement Grant
Oppenheimer Sticks to Their Buy Rating for Savara (SVRA)
Savara Inc. (SVRA) Reports Q1 Financial Results
5 Best Penny Stocks to Buy for Long Term
Guggenheim Reaffirms Their Buy Rating on Savara (SVRA)
Savara (SVRA) Receives a Buy from Piper Sandler

New MarketBeat Followers Over Time

Media Sentiment Over Time

Galectin Therapeutics stock logo

Galectin Therapeutics NASDAQ:GALT

$4.24 -0.73 (-14.69%)
As of 02:34 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$31.57 -0.24 (-0.77%)
As of 02:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Schrodinger stock logo

Schrodinger NASDAQ:SDGR

$16.31 -1.08 (-6.20%)
As of 02:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Savara stock logo

Savara NASDAQ:SVRA

$6.16 +0.13 (+2.07%)
As of 02:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.